Scheme 1 Proposed mechanism.
However, aliphatic terminal alkynes, such as 1-hexyne, did not
give the desired product under the standard conditions.
3 (a) B. Kalluraya and S. Sreenivasa, Il Faemaco, 1998, 53, 399–404;
(b) D. Dube, M. Blouin, C. Brideau, C. Chan, S. Desmarais,
D. Ethier, J. Falgueyret, R. W. Friesen, M. Girard, Y. Girard,
J. Guay, D. Riendeau, P. Tagari and R. N. Young, Bioorg. Med.
Chem. Lett., 1998, 8, 1255–1260.
´
A possible mechanism of this transformation is proposed in
Scheme 1.14 The first step is the oxidative addition of Pd(0)
with aryl halide. The presence of an ortho-b-acyl-enamine
group as a ligand makes this step easier (I). Coordination of
the alkyne to the ArPdOR complex then followed. Because no
copper salt is employed, and the bases are not strong enough
to abstract a proton from the alkyne, a transmetalation step
may be excluded. The terminal alkyne C–H bond activation is
accomplished by the coordination of the alkyne to the
ArPdOR complex. Upon coordination, the C–H bond is
weakened, and HOR is removed from Pd(II) in the presence
of a base to form an arylalkynylpalladium species III, which
undergoes reductive elimination to afford the product IV
regenerating the catalyst. Product IV then undergoes a base
catalyzed alkyne carbocyclization15 process to afford V, which
then isomerizes to the target compound 3.
4 (a) I. L. Baraznenok, V. G. Nenajdenko and E. S. Balenkova, Eur.
J. Org. Chem., 1999, 937–941; (b) B. Crousse, J. Begue and
D. Bonnet-Delpon, J. Org. Chem., 2000, 65, 5009–5013;
(c) J. Takaya, H. Kagoshima and T. Akiyama, Org. Lett.,
2000, 2, 1577–1579; (d) T. Fuchigami and S. Ichikawa, J. Org.
Chem., 1994, 59, 607–615; (e) M. Schlosser, H. Keller, S. Sumida
and J. Yang, Tetrahedron Lett., 1997, 38, 8523–8526;
(f) E. J. Latham, S. M. Murphy and S. P. Stanforth, Tetrahedron
Lett., 1994, 35, 3395–3396; (g) L. Strekowski, S. Lin, H. Lee,
Z. Zhang and J. C. Mason, Tetrahedron, 1998, 54, 7947–7954;
(h) L. Strekowski, A. Czarny and H. Lee, J. Fluorine Chem., 2000,
104, 281–284.
5 (a) R. Filler and Y. Kobayashi, in Organofluorine Compounds
in Medicinal Chemistry and Biomedical Applications, ed.
L. M. Yagupolskii, Elsevier, New York, 1993, p. 1; (b) T. Hiyama,
in Organofluorine Compounds: Chemistry and Applications, ed.
H. Yamamoto, Springer-Verlag, Berlin, 2000, p. 137.
6 (a) J. B. Dickey, R. N. Y and J. M. McNally, US 2432393,
Dec 1947; (b) M. S. Raasch, J. Org. Chem., 1962, 27,
1406–1409.
7 Y. Kobayashi and I. Kumadaki, Tetrahedron Lett., 1969, 10,
4095–4096.
8 (a) R. J. Linderman and K. S. Kirollos, Tetrahedron Lett., 1990,
31, 2689–2692; (b) H. Keller and M. Schlosser, Tetrahedron, 1996,
52, 4637–4644.
9 (a) H. Amii, Y. Kishikawa and K. Uneyama, Org. Lett., 2001, 3,
1109–1112; (b) A. Isobe, J. Takagi, T. Katagiri and K. Uneyama,
Org. Lett., 2008, 10, 2657–2659.
10 S. Fustero, B. Pina, M. Garcia de la Torre, A. Navarro,
C. Ramirez de Arellano and A. Simon, Org. Lett., 1999, 1,
977–980.
In conclusion, we have designed a new, rapid, and high-yielding
synthetic approach to 3,4-disubstituted 2-trifluoromethylquino-
lines via a tandem Sonogashira–alkyne carbocyclization process
under extremely mild conditions, in which two new C–C bonds
are formed during a one-pot procedure, and it works well
with non-fluorine containing substrates. In addition, the
NHC(CF3)QCHCOR structure has a strong ortho-substituent
chelating effect on the Sonogashira C–C bond formation process.
This work was supported by the National Science Founda-
tion of China (Nos. 20532040 and 20772145).
11 Y. Wu, Y. Li and J. Deng, Tetrahedron Lett., 2005, 46, 5357–5360.
12 Q. Cai, B. Zou and D. Ma, Angew. Chem., Int. Ed., 2006, 45,
1276–1279.
Notes and references
1 J. P. Michael, Nat. Prod. Rep., 2001, 18, 543–559.
2 (a) R. D. Larsen, E. G. Corley, A. O. King, J. D. Carroll, P. Davis,
T. R. Verhoeven, P. J. Reider, M. Labelle, J. Y. Gauthier,
Y. B. Xiang and R. J. Zamboni, J. Org. Chem., 1996, 61,
3398–3405; (b) Y. Chen, K. Fang, J. Sheu, S. Hsu and C. Tzeng,
J. Med. Chem., 2001, 44, 2374–2377; (c) G. Roma, M. Di Braccio,
G. Grossi, F. Mattioli and M. Ghia, Eur. J. Med. Chem., 2000, 35,
1021–1035.
13 (a) D. Sole
metallics, 2006, 25, 1995–2001; (b) J. Vicente, M. Chicote,
A. Martınez-Martınez, P. G. Jones and D. Bautista, Organo-
´
, S. Diaz, X. Solans and M. Font-Bardia, Organo-
´
metallics, 2008, 27, 3254–3271.
14 J. Cheng, Y. Sun, F. Wang, M. Guo, J. Xu, Y. Pan and Z. Zhang,
J. Org. Chem., 2004, 69, 5428–5432.
15 R. Bernini, S. Cacchi, G. Fabrizi, E. Filisti and A. Sferrazza,
Synlett, 2009, 1245–1250.
ꢀc
This journal is The Royal Society of Chemistry 2010
Chem. Commun., 2010, 46, 2145–2147 | 2147